1. Market Research
  2. > Pathology
28 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Analyzing the Global Market for Active Pharmaceutical Ingredients 2018

  • $ 1200
  • October 2018
  • 390 pages

Under Oncology, the company is developing CTL## for pediatric acute lymphoblastic leukemia and large B-cell lymphoma; LCI## for Cushing' s disease; ABL## for Chronic myeloid leukemia; INC## for Non-small cell lung cancer; BYL## for advanced breast cancer; Jakavi for Graftversus-hos

  • Biotechnology
  • Lymphoma
  • Pharmaceutical
  • Market Size
  • Teva Pharmaceutical Industries Ltd.

Analyzing the Global CNS Market 2018

  • $ 1000
  • April 2018
  • 175 pages

lymphoma; ZYTIGA (abiraterone acetate), a treatment for metastatic castration-resistant prostate cancer; IMBRUVICA (ibrutinib), an oral, oncedaily therapy approved for use in treating certain B-cell malignancies or blood cancers, and Waldenstrom' s Macroglobulinemia; PROCRIT (epoetin al

  • Infectious Disease
  • Lymphoma
  • Pain Relief
  • Psychotic Disorder
  • Therapy

Market for Active Pharmaceutical Ingredients in Japan - Forecast and Analysis 2018

  • $ 850
  • November 2018
  • 145 pages

Under Oncology, the company is developing CTL## for pediatric acute lymphoblastic leukemia and large B-cell lymphoma; LCI## for Cushing' s disease; ABL## for Chronic myeloid leukemia; INC## for Non-small cell lung cancer; BYL## for advanced breast cancer; Jakavi for Graftversus-hos

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Allergan plc
  • Novartis AG

Analyzing Generics Market in Canada 2017

  • $ 850
  • August 2017
  • 90 pages

In February 2015, the company discontinued SAR-##, which was in Phase I trial for the treatment of advanced solid tumors or lymphomas, metastatic braf-mutated melanoma and PTEN deficient tumors.

  • Lymphoma
  • Pharmaceutical
  • Allergan plc
  • Apotex Inc.
  • Mylan Inc.

Pharmaceutical Industry in the United States 2018

  • $ 850
  • September 2018
  • 150 pages

As of February 2017, Merck has ## programs in Phase II stage for asthma, ovarian cancer, advanced solid tumors, nasopharyngeal cancer, primary mediastinal large Bcell lymphoma, prostate cancer, cough, including cough with idiopathic pulmonary fibrosis, diabetes mellitus, hepatitis C and pne

  • Lymphoma
  • Pharmaceutical
  • Allergan plc
  • Merck & Co., Inc.
  • Mylan Inc.

Market for Active Pharmaceutical Ingredients in China - Forecast and Analysis 2018

  • $ 850
  • October 2018
  • 160 pages

Under Oncology, the company is developing CTL## for pediatric acute lymphoblastic leukemia and large B-cell lymphoma; LCI## for Cushing' s disease; ABL## for Chronic myeloid leukemia; INC## for Non-small cell lung cancer; BYL## for advanced breast cancer; Jakavi for Graftversus-hos

  • Lymphoma
  • Pharmaceutical
  • Allergan plc
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

Analyzing Generics Market in France 2017

  • $ 850
  • August 2017
  • 95 pages

In February 2015, the company discontinued SAR-##, which was in Phase I trial for the treatment of advanced solid tumors or lymphomas, metastatic braf-mutated melanoma and PTEN deficient tumors.

  • Lymphoma
  • Pharmaceutical
  • Allergan plc
  • Mylan Inc.
  • Sandoz Inc.

Analyzing Generics Market in Brazil 2017

  • $ 850
  • March 2017
  • 70 pages

In February 2015, the company discontinued SAR-##, which was in Phase I trial for the treatment of advanced solid tumors or lymphomas, metastatic braf-mutated melanoma and PTEN deficient tumors.

  • Lymphoma
  • Pharmaceutical
  • Allergan plc
  • Sanofi S.A.
  • Servier

Analyzing the Global Generics Industry 2017

  • $ 1000
  • March 2017
  • 440 pages

These drugs are used to treat certain diseases such as cancers (leukemia, lymphomas), epilepsy, multiple sclerosis, psychological disorders, Parkinson' s disease in outpatient care.

  • Lymphoma
  • Pharmaceutical
  • Forecast
  • Mylan Inc.
  • Teva Pharmaceutical Industries Ltd.

Analyzing Generics Market in Germany 2017

  • $ 850
  • August 2017
  • 95 pages

© Aruvian Research List of Figures List of Tables A.

  • Lymphoma
  • Pharmaceutical
  • Allergan plc
  • Aspen Pharmacare Holdings Limited
  • Mylan Inc.

Analyzing Generics Market in Japan 2017

  • $ 850
  • March 2017
  • 85 pages

In February 2015, the company discontinued SAR-##, which was in Phase I trial for the treatment of advanced solid tumors or lymphomas, metastatic braf-mutated melanoma and PTEN deficient tumors.

  • Lymphoma
  • Pharmaceutical
  • Allergan plc
  • Daiichi Sankyo Company
  • Sanofi S.A.

Analyzing Generics Market in South Africa 2017

  • $ 850
  • March 2017
  • 80 pages

In February 2015, the company discontinued SAR-##, which was in Phase I trial for the treatment of advanced solid tumors or lymphomas, metastatic braf-mutated melanoma and PTEN deficient tumors.

  • Lymphoma
  • Pharmaceutical
  • Adcock Ingram Holdings Limited
  • Aspen Pharmacare Holdings Limited
  • Cipla Ltd

Analyzing Generics Market in China 2017

  • $ 850
  • March 2017
  • 95 pages

In February 2015, the company discontinued SAR-##, which was in Phase I trial for the treatment of advanced solid tumors or lymphomas, metastatic braf-mutated melanoma and PTEN deficient tumors.

  • Lymphoma
  • Pharmaceutical
  • Cipla Ltd
  • Mylan Inc.
  • Sanofi S.A.

Analyzing Generics Market in India 2017

  • $ 850
  • March 2017
  • 100 pages

In February 2015, the company discontinued SAR-##, which was in Phase I trial for the treatment of advanced solid tumors or lymphomas, metastatic braf-mutated melanoma and PTEN deficient tumors.

  • Lymphoma
  • Pharmaceutical
  • Aurobindo Pharma Limited
  • Cipla Ltd
  • Mylan Inc.

Analyzing the Global Diabetes Market 2016

  • $ 1000
  • September 2016
  • 195 pages

IN FEBRUARY 2015, THE COMPANY DISCONTINUED SAR-##, WHICH WAS IN PHASE I TRIAL FOR THE TREATMENT OF ADVANCED SOLID TUMORS OR LYMPHOMAS, METASTATIC BRAF-MUTATED MELANOMA AND PTEN DEFICIENT TUMORS.

  • Antidiabetics
  • Diabetes
  • Insulin
  • Lymphoma
  • United States

Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry 2017

  • $ 850
  • March 2017
  • 195 pages

In February 2015, the company discontinued SAR-##, which was in Phase I trial for the treatment of advanced solid tumors or lymphomas, metastatic braf-mutated melanoma and PTEN deficient tumors.

  • Generic Drug
  • Lymphoma
  • Pharmaceutical
  • Mylan Inc.
  • Teva Pharmaceutical Industries Ltd.

Analyzing Generics Market in Australia 2017

  • $ 850
  • March 2017
  • 85 pages

Analyzing Generics Market in Australia 2017 © Aruvian Research List of Figures List of Tables A.

  • Lymphoma
  • Pharmaceutical
  • Allergan plc
  • Aspen Pharmacare Holdings Limited
  • Mylan Inc.

Analyzing Generics Market in Italy 2017

  • $ 850
  • August 2017
  • 85 pages

In February 2015, the company discontinued SAR-##, which was in Phase I trial for the treatment of advanced solid tumors or lymphomas, metastatic braf-mutated melanoma and PTEN deficient tumors.

  • Lymphoma
  • Pharmaceutical
  • Allergan plc
  • Mylan Inc.
  • Sandoz Inc.

Analyzing Generics Market in Indonesia 2017

  • $ 850
  • August 2017
  • 95 pages

© Aruvian Research List of Figures List of Tables A.

  • Lymphoma
  • Pharmaceutical
  • Allergan plc
  • Cipla Ltd
  • Teva Pharmaceutical Industries Ltd.

Analyzing the Global Biosimilars Industry 2016

  • $ 1100
  • July 2016
  • 285 pages

OTHER DISEASES THAT ARE TREATED WITH INTERFERON ALFA ARE HAIRY CELL LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, MULTIPLE MYELOMA, FOLLICULAR LYMPHOMA, CARCINOID TUMOR AND MALIGNANT MELANOMA.

  • Biopharmaceutical
  • Biosimilar
  • Lymphoma
  • Medical Biotechnology
  • Pharmaceutical
View report >

Lymphoma Statistics in the UK

  • January 2018
  • 6 pages

(observed and ##. ##% five years from a lymphoma diagnosis in 2009-2013.

  • Cancer
  • Lymphoma
  • United Kingdom
  • Demographic

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on